Tracer library / [177Lu]Lu-DOTA-TRK-950
[177Lu]Lu-DOTA-TRK-950
Also written as [Lu-177]Lu-DOTA-TRK-950
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated anti-CAPRIN-1 monoclonal antibody (radioimmunoconjugate)
- Target / mechanism
- Targets CAPRIN-1, a cancer-specific cell surface antigen PMID 40473914
- Clinical application
- Solid cancers expressing CAPRIN-1 (e.g., breast cancer and colorectal cancer models) PMID 40473914
- Theranostic pair
- [111In]DOTA-TRK-950
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | ≥ 95% | TRK-950-DOTA ITM | 40473914 2025 J Cancer Res Clin Oncol Radiolabeling with 177Lu was performed using a modified version of the above method. |
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- ITM
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-TRK-950, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40473914. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40473914: 'TRK-950-DOTA'. Stage set/updated at stage 39 from PMID 40473914: 'In this proof-of-concept study, we prepared radiolabeled form of TRK-950 and investigated their potential as tumor imaging or therapeutic agents.'.